Baidu
map

两会专访:重传承重服务抓机遇,推动中医药发展

2018-03-12 黄蓓 中国中医

今年两会期间,国家中医药管理局副局长于文明委员从中医药传统知识保护、提高中医药服务能力和中医药服务“一带一路”等方面就政府工作报告中感受最深的内容接受中国中医药报记者专访——国家中医药管理局副局长于文明委员。

今年两会期间,国家中医药管理局副局长于文明委员从中医药传统知识保护、提高中医药服务能力和中医药服务“一带一路”等方面就政府工作报告中感受最深的内容接受中国中医药报记者专访——国家中医药管理局副局长于文明委员。


“今年的政府工作报告强调,支持中医药事业传承发展,这体现了党中央、国务院对中医药事业发展的高度重视和亲切关怀,也是对中医药工作者的极大鼓舞和鞭策。”两会期间,国家中医药管理局副局长于文明委员接受中国中医药报记者专访时,就政府工作报告中感受最深的内容说到。

党的十八大以来,党中央、国务院高度重视中医药事业的发展,不断加强中医药改革发展的战略谋划和顶层设计,把中医药发展列为国家战略,相继出台了一系列政策措施,特别是《中华人民共和国中医药法》《中医药发展战略规划纲要(2016—2030年)》的出台,有力地推动了中医药事业发展,中医药事业发展迎来新的战略机遇期。

站在新时代的历史起点上,怎样发展中医药?如何加强中医药传承工作?发展中医药事业的出发点和落脚点在哪?中医药为什么要“走出去”?怎样才能行稳致远?今年两会期间,于文明带来的《关于加快制定中医药传统知识保护条例的建议》《关于发挥中医药作用,做实做强基层医疗服务的建议》《关于设立中医药“一带一路”专项基金的建议》《关于推进中医药文化国际传播的建议》等提案,或许能给我们答案。

传承发展是责任使命也是基础工作

党的十九大报告提出坚持中西医并重,传承发展中医药事业,为新时代推动中医药振兴发展提供了遵循、指明了方向。今年的政府工作报告提出支持中医药事业传承发展。“两个重要报告都强调‘传承发展’,这是党中央、国务院对中医药工作的战略部署,也体现了党中央、国务院对于中医药发展的重点要求。”于文明说。

传承发展是当前中医药工作的重点,创新应建立在继承的基础上。“没有传承的创新,犹如无根之木、无源之水。推动中医药发展,必须把传承的根基筑牢,系统传承中医药的理论知识和宝贵经验,在继承基础上创新发展,做到‘古为今用、洋为中用’。”于文明说。

中医药理论在当今临床疾病防治中如何发挥作用,传统炮制技术如何传承保护,名老中医学术经验如何保护和应用等一直是于文明关注的课题。此次参会,他再次呼吁加强对中医药传统知识的保护。

于文明认为,中医药传统知识是中华民族的宝贵资源,是中国古代科学瑰宝,是中医药传承发展的核心要素。如何建立一个与现代知识产权制度并行,又相互补充的制度,解决现代知识产权制度不能保护中药炮制技术和名医名方、验方特殊疗效的“弊端”,是今后传承工作的重要课题。

近年来,有关部门已经认识到中医药传统知识专门保护的重要性,特别是中医药法和战略规划纲要中都作出了明确要求,但涉及中医药传统知识保护的核心问题还需要进一步理清和明确。保护什么,怎么保护,惠益分享机制和形式以及权益主体客体如何理清界定等问题,急需在国家层面、保护技术层面和学术层面确立法规制度。

于文明建议,在国家层面加快战略研究,制定《国家中医药传统知识保护条例》,建立健全传统知识保护制度。他指出,要做好这项工作,必须加强战略研究,必须在国家战略层面加强中医药传统知识保护制度的顶层设计,特别是准确界定中医药传统知识的内涵及外延,明确保护什么以及怎么保护等一系列问题,确定权利主体、客体和主要内容,制定相应的权利限制范围和权益,在兼顾中医药传统知识保护的同时,鼓励创新研究和发展应用,明确惠益分享机制和形式。

提高服务能力是切入点也是工作重点

传承发展中医药,突出特色优势,提高中医药服务能力,是中医药事业的价值所在,也是工作重点,而传承发展中医药事业的出发点和落脚点就是服务人民健康事业。

“坚持以人民为中心的发展思想,着力保障和改善民生,人民群众获得感不断增强。”“要在发展基础上多办利民实事、多解民生难事,兜牢民生底线,不断提升人民群众的获得感、幸福感、安全感。”在李克强总理作政府工作报告时,人民大会堂数十次响起热烈掌声。报告中十几次提及“民生”一词,体现了中央政府对民生事业的亲切关怀。

于文明认为,总理报告强调的“提高医疗卫生服务质量,下大力气解决群众看病就医难题”,是政府工作重点,也对中医药工作提出了进一步要求。

建立基本医疗保障制度,提高医疗服务的公平性和可及性,为城乡居民提供安全、有效、方便、价廉的医疗卫生服务,是医改的重要目标。“中医药具有‘五种资源’优势,在基本医疗保障制度中,在维护群众健康,保障和改善民生中有安全、方便、效验、经济的特点,可以在保基本、强基层和控费用方面发挥作用,放大医改的惠民效果”,于文明说,“随着政府供给侧结构调整,中医药以其特色优势和‘五种资源’的特殊地位作用,将在基本医疗和非基本医疗中进一步发挥作用。”

据北京市调查统计,北京市三级中医医院平均每诊疗人次费用为194.34元,而综合医院为303元;骨折中医闭合复位收费仅80元,而西医开放手术收费889元;当中药饮片处方比例增加5%时,医疗保险报销的费用可减少2230万元。

参与服务“一带一路”是国家使命也是发展机遇

近日,一则止咳糖浆在国外受热捧的新闻引起了广泛关注,中医药“走出去”问题再度进入公众视野。关于中医药为什么要“走出去”和怎么“走出去”的问题,于文明谈了他对政府工作报告的一些学习体会。于文明表示,中医药“走出去”,既是响应总书记的号召,参与国家“一带一路”建设的要求,也是让世界认识中医药、了解中医药的机会,同时还有利于加强国际学术交流,促进中医药原创思维与现代科技融合,让中医药更好地为人类健康服务。

习近平总书记提出“一带一路”倡议后,国家出台了一系列战略举措,顺应时代发展的要求,特别是国家推进“一带一路”建设工作领导小组审议通过了《中医药“一带一路”发展规划(2016—2020年)》,为中医药参与服务“一带一路”指明了方向,提出了要求。规划明确,到2020年,中医药“一带一路”全方位合作新格局基本形成,与沿线国家合作建设30个中医药海外中心,颁布20项中医药国际标准,注册100种中药产品,建设50家中医药对外交流合作示范基地。中医药的医疗与养生保健价值被沿线民众广泛认可,越来越多的沿线国家提出与中国加强合作。

规划实施一年多来,在外交部、财政部、发改委等部门支持下,我国已经建立了17个海外中医药中心,中医药已经成为“一带一路”建设的重要特色组成部分,促进了沿线国家民心相通。

但是,由于中医药国际专项经费数额较小,政府财政资金使用受限,导致规划难以发挥最大效用,难以更好地参与服务“一带一路”建设和促进中医药国际化、市场化运行。基于此,于文明今年再次呼吁,要建立中医药“一带一路”专项基金,引导社会资本积极参与,充分发挥财政资金与社会资本的协同作用,激发市场在资源配置中的决定性作用,让中医药更好地助力于国家“一带一路”倡议的实施。

于文明表示,今年是贯彻党的十九大精神的开局之年,是改革开放40周年,是决胜全面建成小康社会、实施健康中国战略及“十三五”规划承上启下的关键一年,我们应该认真落实党的十九大报告和政府工作报告对传承发展中医药事业的要求,发挥中医药在服务人民健康、加快实施健康中国战略中的重要作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-12-13 lishizhe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-14 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-13 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1993400, encodeId=d00f199340003, content=<a href='/topic/show?id=be0921510a0' target=_blank style='color:#2F92EE;'>#中医药发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21510, encryptionId=be0921510a0, topicName=中医药发展)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Tue Jul 17 15:57:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703293, encodeId=09db1e032930b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Aug 11 05:57:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675576, encodeId=f8a016e557651, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Dec 13 02:57:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409412, encodeId=497d140941298, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Mar 14 12:57:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295716, encodeId=f28a295e160c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 13 06:52:14 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295608, encodeId=86fe2956086d, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Mar 12 22:40:33 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-12 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

Baidu
map
Baidu
map
Baidu
map